Clinical Trial Update: Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Acoltremon ophthalmic solution 0.003% for signs and symptoms of ocular surface disease in patients with Stage I neurotrophic k…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurotrophic Keratopathy
• Ocular Surface Disease

Drugs mentioned

• Acoltremon ophthalmic solution 0.003% (Acoltremon)

Snippet

Sponsor: University of South Florida | Conditions: Ocular Surface Disease, Neurotrophic Keratopathy Stage 1 | Phase 4 | Status: RECRUITING